Delax

Quick links to important sections

Delax

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delax

Quick Facts: Delax

Property Description
Active ingredient Chlormezanone
Form Oral tablet
Pharmacological class Centrally Acting Skeletal Muscle Relaxant / Anxiolytic Agent
General purpose Relieving muscle tension and nervous overactivity
Origin Synthetic, non-benzodiazepine derivative

Delax: Classification and Chemical Composition

Delax is a synthetic, single-ingredient medicinal agent formulated as an oral tablet for systemic absorption, whose key active component is the substance Chlormezanone. It is primarily classified as a centrally acting skeletal muscle relaxant and is also recognized for its anxiolytic (anti-anxiety) properties. The dual classification of Chlormezanone has historically positioned it as an agent for relieving tension that has both a physical and emotional component, a key differentiating factor in its pharmacological profile.

The chemical core of Delax is the active ingredient Chlormezanone, defined as a non-benzodiazepine derivative within the 4-metathiazanone S,S-dioxide chemical class. Chlormezanone is grouped under 'Centrally acting agents' in standard pharmacological classifications. This medicine is clinically recognized for its ability to affect the central nervous system, leading to its therapeutic outcomes. As a single-ingredient product, it delivers a measured amount of the active compound via the oral route of administration, ensuring a consistent profile for achieving its desired effect across the nervous and muscular systems.


The Dual Purpose of Delax (Chlormezanone)

The general purpose of Delax is to provide relief from conditions involving both involuntary physical tension and the associated nervous overactivity due to its inherent dual pharmacological action. This medicine aims to manage both the physical manifestation of tension (such as muscle spasm or stiffness) and the underlying nervous distress that may accompany it.

Delax achieves this benefit by functioning as a central nervous system depressant, gently quieting heightened nerve activity in the brain and spinal cord, including inhibiting polysynaptic reflexes. The resulting combined effect is both muscle relaxation and a mild sedative effect. Chlormezanone is characterized as an effective treatment for general anxiety, muscle spasm, and tension. This confirms the medicine helps alleviate physical discomfort that originates from or is aggravated by nervous tension.

What side effects are possible with Delax?

Possible Side Effects and Safety Information

The safety profile of Delax (Chlormezanone) is primarily characterized by effects related to Central Nervous System (CNS) depression and a documented risk of rare but serious hypersensitivity reactions. This section outlines the officially listed adverse effects and safety characteristics as classified in regulatory documents.


Regulatory Adverse Reactions

Adverse reactions are officially documented across several System-Organ Classes (SOCs):

System-Organ Class Common Adverse Reactions
Nervous System Disorders Drowsiness, Dizziness, General Weakness
Gastrointestinal Disorders Nausea, Abdominal Pain

Serious adverse reactions, which are classified as rare to very rare, include Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). The official safety documentation also lists the potential for severe liver damage (hepatotoxicity).


Safety Considerations by Population and Duration

Regulatory documents include specific considerations for certain patient groups and duration of use:

  • Older Adults: Psychiatric effects, such as confusion and mood swings, are officially noted to be more likely in this population.
  • Hepatic Impairment: Caution is necessary in patients with severe liver function impairment due to the drug's metabolism and the documented risk of liver disorders.
  • Duration of Use: Prolonged use is associated with the potential for developing dependency and subsequent withdrawal symptoms upon cessation.

These safety classifications emphasize the need to understand the drug's potential for CNS effects and the mandatory awareness of the rare, life-threatening skin reactions that form a key constraint on its use.

Overdose and Emergency Response

Delax Overdose and When to Seek Help

The official regulatory profile describes overdose as characterized by manifestations of severe Central Nervous System (CNS) depression. Documented clinical signs include drowsiness, dizziness, and pronounced muscle weakness. Gastrointestinal symptoms such as nausea and abdominal pain have also been reported. Over-exposure to the medication may affect the hepatic, renal, and metabolic systems, with specific laboratory findings documenting hyperglycemia or hypoglycemia in severe cases.

Overdose has the potential for severe and life-threatening outcomes, which include the progression to coma, death, and the development of cerebral edema. Critically, life-threatening systemic reactions such as Toxic Epidermal Necrolysis (TEN) are cited by regulatory authorities as a severe risk of drug toxicity.

It is officially mandated to seek immediate medical attention for any suspected overdose or the onset of severe systemic manifestations. Management is strictly constrained, as no specific antidote is known. Treatment is universally symptomatic and supportive. Hospital-level procedural measures may include gastric lavage or administration of activated charcoal to limit absorption, and continuous monitoring of vital signs is required in cases of severe poisoning until stabilization.

Therapeutic Uses of Delax

Delax may help manage the symptoms of various chronic conditions that can affect a patient's daily functions. It is indicated for use in adults experiencing persistent discomfort and pain in scenarios such as long-term musculoskeletal issues, certain neuropathic discomforts, and inflammatory-related conditions. Delax can assist in reducing the severity and frequency of these symptoms.

Quick Fact: Relief for Persistent Pain

Delax is also a therapeutic option for individuals dealing with acute pain episodes resulting from temporary injuries or common physical strains. When integrated into a comprehensive care plan, Delax is intended to help patients maintain functional independence and support their overall quality of life.

Eligibility and Restrictions for Use

The eligibility profile for Delax (Chlormezanone) is defined by a definitive regulatory action: absolute prohibition for use by the general population in major global markets. This restriction stems from the drug's official withdrawal and discontinuation by manufacturers and regulatory bodies due to an unacceptable safety profile.

Contraindicated Populations and Conditions

Use of Delax is contraindicated and prohibited for virtually all patient groups. This non-eligibility is specifically mandated for individuals with a history of or predisposition to Severe Cutaneous Adverse Reactions (SCARs), including the life-threatening conditions Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Furthermore, the medicine is prohibited for patients with pre-existing severe hepatic impairment due to the documented risk of serious liver disorders.

Age and Special Population Rules

The prohibition extends across all age ranges. The use of Delax is considered not established and prohibited for children, adolescents, and older adults. Similarly, use during pregnancy and breastfeeding is prohibited, as the serious risks cited in regulatory withdrawal actions are deemed unacceptable for these vulnerable populations. Regulatory authorities determined that standard risk-mitigation measures were insufficient to ensure safety.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This information addresses only documented interactions for Delax (Bisacodyl), based on authoritative government regulatory sources.

Drug-Drug and Drug-Food Interactions

Regulatory documents emphasize two core types of interactions: those affecting the absorption of the tablet and those causing additive pharmacodynamic effects.

Interacting Substance/Class Interaction Mechanism/Result Administration Requirement
Antacids or Milk Premature dissolution of the enteric coating, which may cause gastric irritation or reduced efficacy. Separate administration by one hour.
Diuretics (e.g., Thiazides) Additive risk of fluid and electrolyte abnormalities, particularly hypokalemia. Use with caution. Monitor electrolyte balance.
Corticosteroids Additive risk of hypokalemia due to enhanced electrolyte loss. Use with caution. Monitor electrolyte balance.
Other Laxatives Increased risk of excessive fluid and electrolyte loss. Avoid concomitant use unless specifically advised.

Population and Contextual Notes

Caution is advised for patients taking medications known to increase the risk of fluid and electrolyte disturbances. This includes the elderly or those with pre-existing conditions that predispose them to electrolyte imbalance. These specific interaction constraints are officially documented to maintain the intended efficacy and safety profile of the drug.

Mechanism of Action

Central Modulation of Inhibitory Signals

Delax's primary mechanism is the positive allosteric modulation of the central GABA-A receptor complex. By binding to a specific modulatory site, the active ingredient Chlormezanone enhances the inhibitory action of the natural neurotransmitter GABA. This interaction facilitates the influx of negatively charged chloride ions ( Cl^-), causing rapid neuronal hyperpolarization across the central nervous system (CNS). This systemic reduction in nerve cell excitability is the basis of the drug's pharmacological profile, modulating activity in systems like the Ascending Reticular Activating System (ARAS).

Influencing Spinal Reflex Pathways

The generalized CNS inhibition extends to the spinal cord, influencing the activity of polysynaptic reflex arcs. This mechanistic domain dictates the drug's effect on muscle control. Modulation of these multi-synaptic circuits decreases the involuntary efferent signaling that contributes to muscle tension, leading to a physiological decrease in skeletal muscle tone.

Multimodal Pharmacological Action

Chlormezanone has also been observed to act as an agonist at the Translocator Protein (TSPO), providing a secondary molecular pathway that complements its primary GABAergic action. This multimodal engagement of different biological systems contributes to the drug's comprehensive range of physiological effects.

Dosage and Administration Information

The administration of Delax (Chlormezanone) is based on the principles defined for its use in clinical practice. The medicine is supplied for oral administration as an uncompounded tablet. The treatment protocol involves a structured dosing schedule that aims to maintain a consistent level of the active ingredient throughout the day. For adults, the total daily dosage ranges from 100 milligrams (mg) to 400 mg. This total amount is not intended for single administration; instead, it must be divided and taken in two to three separate doses per 24-hour period, a frequency pattern established to support the drug's pharmacological profile.

Tailored guidelines exist for certain populations. A distinct, reduced regimen is established for use only in children over five years of age, where the typical dose is 50 mg to 100 mg, three times a day.

Furthermore, specific parameters govern the conclusion of therapy. To cease treatment with Delax, the dosage is gradually lowered (tapered) over time to ensure the discontinuation aligns with clinical guidance. Abrupt cessation of the medicine is restricted. The overall course of use is typically short-term for acute manifestations of tension or may be used as an adjunct within a longer-term management framework. These descriptions define the parameters for how the medication is utilized in patient care.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Delax (Chlormezanone)

This overview describes the research landscape for Delax, focusing on the types of studies that have been conducted and the specific areas that research has explored. Study results reflect the specific conditions under which they were conducted and findings describe group patterns, not personal outcomes.

1. Evidence for Use in Managing Muscle Tension and Pain

Research has primarily used Controlled Clinical Trials and some Randomized Controlled Trials (RCTs). These studies focused on adults experiencing muscle spasm and involuntary physical tension often associated with long-term musculoskeletal issues or temporary physical strains. The research examined outcomes related to physical discomfort, including patient-reported pain intensity scores and symptom patterns in the observed populations.

The studies were generally conducted during periods of increased symptom activity and often involved short-term follow-up periods. Findings describe patterns observed in the studies, though results were sometimes mixed when compared to placebo.

2. Evidence for Use in Addressing General Anxiety and Nervous Tension

Delax was studied for its historical use as a compound with anxiolytic properties. Research has involved Controlled Clinical Trials and historical Double-Blind Studies that were applied in studies examining adults with general anxiety, nervous overactivity, and tension. The research examined outcomes linked to psychological strain, using standardized rating scales to measure anxiety scores and assessing sleep disturbance.

Studies reported how symptoms evolved in the observed populations, including data measured on anxiety scales and patterns related to sleep parameters. The consistency of the observed patterns in the evidence base is not fully established.

6. Research Gaps and What is Still Uncertain About Delax Studies

The evidence quality varies across studies, with many controlled trials being older, and their methodologies may differ from modern standards. Sample sizes were modest in some of the foundational studies, and comparative evidence is lacking when assessing Delax against other agents in its pharmacological class. These limitations mean the existing studies provide limited insight into long-term effects, and certainty remains low regarding observed patterns in certain patient subgroups.

Key Studies & References WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification of Chlormezanone (N05BC04)

How should Delax be stored and disposed of?

How to Store and Dispose of Delax (Chlormezanone)

The following rules define the mandatory storage and disposal procedures for Delax (Chlormezanone tablets) as required by official regulatory documents.

Requirement Official Regulatory Statement
Storage Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection/Handling Protect from excessive moisture and avoid freezing. Keep the container tightly closed.
Child Safety Keep out of the sight and reach of children and pets.
Disposal Instructions Dispose of unused medicine preferably through a drug take-back program.

If a take-back program is unavailable, the medicine should be mixed with an unappealing substance like dirt or coffee grounds, sealed in a bag, and then placed in the household trash. Do not flush the medicine down the toilet unless it is specifically on the regulatory flush list. All disposal of contents and containers must align with local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Delax found in:

A-Z Index: